AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12172882 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (CON)
Number of subjects: 62
Study 11465523 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (25-50 mg)
Number of subjects: 47
Study 11465523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 9604124 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg artemisinin
Number of subjects: 8
Study 9604124 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg artemisinin
Number of subjects: 8
Study 9604124 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg artemisinin
Number of subjects: 8
Study 9604124 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin (all doses)
Number of subjects: 8
Study 8067230 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine/bupivacaine (MB) - morphine at 0.2 mg.h‐1 and bupivacaine at 10 mg.h‐1 for the first 24 h, then 5 mg.h‐1 for the second 24 h
Number of subjects: 85
Study 8067230 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl/bupivacaine (FB) - fentanyl at 20 micrograms.h‐1 and bupivacaine at 10 mg.h‐1 for the first 24 h, then 5 mg.h‐1 for the second 24 h
Number of subjects: 85
Study 3267650 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 0
Study 3267650 — intervention group
Group type: EXPERIMENTAL
Intervention: Küntscher-Y nail
Number of subjects: 0
Study 48992 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored visual illustrations
Number of subjects: 261
Study 48992 — intervention group
Group type: EXPERIMENTAL
Intervention: Black and white visual illustrations
Number of subjects: 261
Study 48992 — intervention group
Group type: COMPARATOR
Intervention: Visuals (both black and white and color)
Number of subjects: 261
Study 31707732 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water immersion (∼42°C)
Number of subjects: 10
Study 31707732 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral control immersion (∼33°C)
Number of subjects: 10
Study 30670669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating mesh nebulizer
Number of subjects: 12
Study 30670669 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer
Number of subjects: 12
Study 30670669 — intervention group
Group type: COMPARATOR
Intervention: T-piece configuration
Number of subjects: 12
Study 30670669 — intervention group
Group type: COMPARATOR
Intervention: Large-spacer configuration
Number of subjects: 12
Study 28454801 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100mg daily
Number of subjects: 30449
Study 28454801 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 30449
Study 26424460 — intervention group
Group type: EXPERIMENTAL
Intervention: NtRTI group
Number of subjects: 541
Study 26424460 — intervention group
Group type: EXPERIMENTAL
Intervention: raltegravir group
Number of subjects: 541
Study 26424460 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 541
Study 23727422 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg-1018 (20 mcg rHBsAg + 3000 mcg 1018, a toll‐like receptor 9 agonist) given at 0, 4, and 24 weeks
Number of subjects: 521
Study 23727422 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg-1018
Number of subjects: 521
Study 23727422 — intervention group
Group type: COMPARATOR
Intervention: HBsAg-Eng (4 double-doses of 2×20 mcg rHBsAg + 500 mcg alum given at 0, 4, 8, and 24 weeks)
Number of subjects: 521
Study 21744284 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft with PRP
Number of subjects: 40
Study 21744284 — intervention group
Group type: COMPARATOR
Intervention: Autograft only
Number of subjects: 40
Study 19129506 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet medications at ICH onset
Number of subjects: 282
Study 19129506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 282
Study 17029027 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Academic Intervention (IAI)
Number of subjects: 167
Study 17029027 — intervention group
Group type: COMPARATOR
Intervention: Generic Academic Intervention (GAI)
Number of subjects: 167
Study 15331886 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOF 20%
Number of subjects: 12
Study 15331886 — intervention group
Group type: COMPARATOR
Intervention: Lipovenoes 20%
Number of subjects: 12
Study 11499858 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 11499858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9088076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Epoetin alfa (300 IU/kg twice weekly for 3 weeks)
Number of subjects: 22
Study 9088076 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Epoetin alfa (100 IU/kg twice weekly for 3 weeks plus an i.v. bolus of 200 IU/kg at the first visit)
Number of subjects: 22
Study 8095250 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms MDI
Number of subjects: 20
Study 8095250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3742316 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - ten per cent methohexitone, 25 mg X kg‐1 (n = 20)
Number of subjects: 60
Study 3742316 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - ten per cent methohexitone, 15 mg X kg‐1 (n = 20)
Number of subjects: 60
Study 3742316 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C - one per cent methohexitone, 15 mg X kg‐1 (n = 20)
Number of subjects: 60
Study 3742316 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - ten per cent methohexitone, 25 mg X kg‐1
Number of subjects: 60
Study 3742316 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C - one per cent methohexitone, 15 mg X kg‐1
Number of subjects: 60
Study 30681494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation with TEE
Number of subjects: 80
Study 30681494 — intervention group
Group type: COMPARATOR
Intervention: Cryoballoon ablation without TEE (non-TEE group)
Number of subjects: 80
Study 29550045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily for 6 months) + Aspirin (81 mg for 6 months)
Number of subjects: 18
Study 29550045 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg once daily for 1 month) + Aspirin (81 mg for 6 months)
Number of subjects: 18
Study 27489790 — intervention group
Group type: EXPERIMENTAL
Intervention: Application user group (n = 22)
Number of subjects: 44
Study 27489790 — intervention group
Group type: COMPARATOR
Intervention: Application nonuser group (n = 22)
Number of subjects: 44
Study 25285423 — intervention group
Group type: EXPERIMENTAL
Intervention: SAF irrigation
Number of subjects: 108
Study 25285423 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoActivator
Number of subjects: 108
Study 25285423 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac
Number of subjects: 108
Study 25285423 — intervention group
Group type: EXPERIMENTAL
Intervention: PUI
Number of subjects: 108
Study 25285423 — intervention group
Group type: COMPARATOR
Intervention: Rotary instrumentation
Number of subjects: 108
Study 25285423 — intervention group
Group type: COMPARATOR
Intervention: Rotary instrumentation with various agitation regimens (syringe irrigation with needles, NaviTip FX, manual dynamic irrigation, CanalBrush)
Number of subjects: 108
Study 22794270 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval-mediated learning
Number of subjects: 0
Study 19936713 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 12
Study 19936713 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% CO2 inhalation
Number of subjects: 12
Study 19936713 — intervention group
Group type: COMPARATOR
Intervention: Control day (air inhalation)
Number of subjects: 12
Study 17351275 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% carbohydrate/45% fat diet (15% protein)
Number of subjects: 52
Study 17351275 — intervention group
Group type: COMPARATOR
Intervention: 60% carbohydrate/25% fat diet
Number of subjects: 52
Study 17351275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 52
Study 15653003 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 45 microg combined with levonorgestrel 30 microg
Number of subjects: 212
Study 15653003 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 45 microg combined with levonorgestrel 40 microg
Number of subjects: 212
Study 15653003 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol and levonorgestrel (both doses)
Number of subjects: 212
Study 15653003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 12966473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 0
Study 12966473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intravenously
Number of subjects: 0
Study 12966473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10402244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) as a single agent
Number of subjects: 0
Study 10402244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) in combination with dacarbazine
Number of subjects: 0
Study 10402244 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) in combination with various cytotoxic agents
Number of subjects: 0
Study 10402244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) combined with cisplatin at high doses
Number of subjects: 0
Study 8756735 — intervention group
Group type: COMPARATOR
Intervention: Antithrombin III (AT III) and alpha 2-antiplasmin (alpha 2-AP) activity on day 0 and day 1 post-operation
Number of subjects: 40
Study 8756735 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of AT III and alpha 2-antiplasmin (alpha 2-AP) activity
Number of subjects: 40
Study 1661657 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine free base (5 mumol/min)
Number of subjects: 0
Study 1661657 — intervention group
Group type: EXPERIMENTAL
Intervention: D-arginine free base (5 mumol/min)
Number of subjects: 0
Study 1661657 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride (5 mumol/min)
Number of subjects: 0
Study 1661657 — intervention group
Group type: EXPERIMENTAL
Intervention: D-arginine hydrochloride (5 mumol/min)
Number of subjects: 0
Study 1661657 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine free base (160 mumol/min)
Number of subjects: 0
Study 1661657 — intervention group
Group type: EXPERIMENTAL
Intervention: D-arginine free base (160 mumol/min)
Number of subjects: 0
Study 1661657 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride (160 mumol/min)
Number of subjects: 0
Study 1661657 — intervention group
Group type: EXPERIMENTAL
Intervention: D-arginine hydrochloride (160 mumol/min)
Number of subjects: 0
Study 1661657 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 6136292 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (10 mg twice a day)
Number of subjects: 70
Study 6136292 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg twice a day)
Number of subjects: 70
Study 6136292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 6136292 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 70
Study 6136292 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 70
Study 6136292 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam and Lorazepam
Number of subjects: 70
Study 6136292 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Clobazam, Lorazepam, Placebo)
Number of subjects: 70
Study 3902533 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide inhalation, 500 mcg twice daily
Number of subjects: 99
Study 3902533 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate inhaler, 100 mcg four times daily
Number of subjects: 99
Study 29575090 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPP (strength, agility, plyometric, and secondary prevention exercises)
Number of subjects: 40
Study 29575090 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPP + PERT (SAPP plus perturbation training)
Number of subjects: 40
Study 29575090 — intervention group
Group type: COMPARATOR
Intervention: Both SAPP and SAPP + PERT
Number of subjects: 40
Study 26987975 — intervention group
Group type: EXPERIMENTAL
Intervention: V158866 (5-300 mg single doses; 50-500 mg repeated doses)
Number of subjects: 51
Study 26987975 — intervention group
Group type: EXPERIMENTAL
Intervention: V158866 (300-500 mg/day)
Number of subjects: 51
Study 23494104 — intervention group
Group type: COMPARATOR
Intervention: Ozone therapy
Number of subjects: 60
Study 23494104 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 60
Study 23494104 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (no LLLT or ozone therapy)
Number of subjects: 60
Study 22527063 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil
Number of subjects: 59
Study 22527063 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and fentanyl
Number of subjects: 59
Study 19793142 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted warfarin
Number of subjects: 101
Study 19793142 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) - enoxaparin 1 mg/kg bd
Number of subjects: 101
Study 19793142 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 101
Study 18081914 — intervention group
Group type: EXPERIMENTAL
Intervention: MxA EIA assay
Number of subjects: 51
Study 18081914 — intervention group
Group type: EXPERIMENTAL
Intervention: NAb-positive patients
Number of subjects: 51
Study 16901550 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-deamino 8-D-arginine vasopressin (DDAVP) spray
Number of subjects: 22
Study 11427219 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 23
Study 11427219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9492666 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant psychological therapy
Number of subjects: 73
Study 9492666 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (Control)
Number of subjects: 73
Study 8052077 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0
Study 8052077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3399838 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex condoms used during vaginal intercourse
Number of subjects: 40
Study 31204262 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 342
Study 31204262 — intervention group
Group type: COMPARATOR
Intervention: Impaired Fasting Glucose (IFG)
Number of subjects: 342
Study 31204262 — intervention group
Group type: EXPERIMENTAL
Intervention: Including physical activity in the model
Number of subjects: 342
Study 28965138 — intervention group
Group type: EXPERIMENTAL
Intervention: REC + DVD
Number of subjects: 90
Study 26599707 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (N-acetylcysteine and ascorbate)
Number of subjects: 21
Study 26599707 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (200 μg/m(3) PM2.5)
Number of subjects: 21
Study 26599707 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 21
Study 25433664 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/emtricitabine/efavirenz
Number of subjects: 1045
Study 25433664 — intervention group
Group type: COMPARATOR
Intervention: ZDV/lamivudine/efavirenz
Number of subjects: 1045
Study 22595974 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral absorbable fat-soluble vitamin formulation (OAFSV)
Number of subjects: 23
Study 22595974 — intervention group
Group type: COMPARATOR
Intervention: Conventional fat-soluble vitamin (FSV) supplementation
Number of subjects: 23
Study 19940231 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Rd (single dose)
Number of subjects: 0
Study 19940231 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg Rd (single dose)
Number of subjects: 0
Study 19940231 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg Rd (single dose)
Number of subjects: 0
Study 19940231 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Rd (multiple dose)
Number of subjects: 0
Study 18567166 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 30
Study 18567166 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole plus Amoxicillin
Number of subjects: 30
Study 15764628 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery surgery
Number of subjects: 187
Study 15764628 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery surgery
Number of subjects: 187
Study 12632889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (group A, 72 patients) starting 15 days after CABG
Number of subjects: 103
Study 12632889 — intervention group
Group type: COMPARATOR
Intervention: No cardiac rehabilitation (group B, 31 patients)
Number of subjects: 103
Study 12632889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (group A)
Number of subjects: 103
Study 10227630 — intervention group
Group type: COMPARATOR
Intervention: 25 mug/kg BDNF
Number of subjects: 1135
Study 10227630 — intervention group
Group type: COMPARATOR
Intervention: 100 mug/kg BDNF
Number of subjects: 1135
Study 10227630 — intervention group
Group type: COMPARATOR
Intervention: 100 mug/kg BDNF (in patients with baseline forced vital capacity of <91%)
Number of subjects: 1135
Study 10227630 — intervention group
Group type: COMPARATOR
Intervention: 100 mug/kg BDNF (in patients reporting altered bowel function)
Number of subjects: 1135
Study 7782581 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment for cervical intraepithelial neoplasia
Number of subjects: 1114
Study 7782581 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1114
Study 2212146 — intervention group
Group type: EXPERIMENTAL
Intervention: Viprostol
Number of subjects: 57
Study 2212146 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 57
Study 2212146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 321991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethothiazine, 60 mg/day for 2 to 3-4 months
Number of subjects: 0
Study 321991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31974939 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple conjunction search task (Task 2)
Number of subjects: 0
Study 31974939 — intervention group
Group type: EXPERIMENTAL
Intervention: Plus conjunction search task (Task 2)
Number of subjects: 0
Study 31974939 — intervention group
Group type: COMPARATOR
Intervention: Comparison between triple and plus conjunction search tasks
Number of subjects: 0
Study 30326732 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-s TASER shock
Number of subjects: 0
Study 30326732 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26886509 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Incision Sling (SIS)
Number of subjects: 48
Study 26886509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-Free Transobturator Suburethral Tape (TVT-O)
Number of subjects: 48
Study 25249789 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 294
Study 25249789 — intervention group
Group type: COMPARATOR
Intervention: MAC-guided anesthesia
Number of subjects: 294
Study 23168581 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA 290 (2 mg, intravenous, three times weekly for 4 weeks)
Number of subjects: 22
Study 23168581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20164296 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 10 mg daily
Number of subjects: 93
Study 20164296 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg sc daily
Number of subjects: 93
Study 20164296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both alendronate and teriparatide
Number of subjects: 93
Study 18478937 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose thymopentin (10 mg/d) combined with trans-artery chemoembolization (TACE) with oxaliplatin 150 mg, pharmorubicin 50 mg, 5‐Fu 750 mg, CF 300 mg and lipiodol 20 ml.
Number of subjects: 50
Study 18478937 — intervention group
Group type: COMPARATOR
Intervention: Trans-artery chemoembolization (TACE) with oxaliplatin 150 mg, pharmorubicin 50 mg, 5‐Fu 750 mg, CF 300 mg and lipiodol 20 ml.
Number of subjects: 50
Study 18478937 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose thymopentin (10 mg/d) combined with TACE.
Number of subjects: 50
Study 18478937 — intervention group
Group type: COMPARATOR
Intervention: Trans-artery chemoembolization (TACE) with oxaliplatin, pharmorubicin, 5‐Fu, CF and lipiodol.
Number of subjects: 50
Study 16305967 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling in Baihui (DU20), Shuigou (DU26) and Shenmen (HT7)
Number of subjects: 10
Study 16305967 — intervention group
Group type: COMPARATOR
Intervention: Routine acupoints for hemiplegia (control group)
Number of subjects: 10
Study 12152996 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/mq (days 1, 8 and 15) as a single agent for 3 monthly courses
Number of subjects: 16
Study 12152996 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/mq (days 1, 8 and 15) plus cisplatin 80 mg/mq (day 1)
Number of subjects: 16
Study 12152996 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 16
Study 12152996 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to treatment failure (TTF)
Number of subjects: 16
Study 10622647 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 2x ED95
Number of subjects: 20
Study 10622647 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 3x ED95
Number of subjects: 20
Study 10622647 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (both doses)
Number of subjects: 20
Study 8622102 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 8 or 15 mg/kg once daily
Number of subjects: 185
Study 8622102 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily
Number of subjects: 185